Literature DB >> 1901256

Cytochrome P-450-dependent vasodilator responses to arachidonic acid in the isolated, perfused kidney of the rat.

A O Oyekan1, J C McGiff, J Quilley.   

Abstract

Pretreatment of phenylephrine (0.5 microM)-preconstricted, isolated perfused kidneys of the male rat with indomethacin (2.8 microM) or BM 13.177 (20 microM) abolished the vasoconstrictor response to arachidonic acid (AA), uncovering a vasodilator response. BW 755C (25 microM), a dual cyclooxygenase/lipoxygenase inhibitor, did not modify the vasodilator effect of AA, whereas 5,8,11,14-eicosatetraynoic acid (10 microM), which blocks all pathways of AA metabolism, abolished AA-induced vasodilation, thus suggesting the involvement of nonlipoxygenase AA metabolites. Clotrimazole (0.7 microM) and 7-ethoxyresorufin (1 microM), both considered to be specific inhibitors of the cytochrome P-450 monooxygenase enzymes, inhibited the vasodilator effect, suggesting that AA-induced renal vasodilation is mediated by one or more cytochrome P-450-derived AA metabolites. None of these interventions affected the vasodilator responses to acetylcholine (100 ng) and nitroprusside (1 microgram). Denudation of the endothelium with CHAPS (10 mg/l) reduced the vasodilator responses to AA, suggesting a requirement of an intact endothelium, whereas inhibition of guanylate cyclase with methylene blue (10(-4) M) was without effect, suggesting that cGMP was not involved in the vasodilator response to AA. The AA-induced renal vasodilation was accompanied by the generation of biologically active material or materials released into the renal effluent, which relaxed endothelium-intact and endothelium-denuded rings of isolated aorta and mesenteric and celiac arteries of the rabbit. These results suggest that in the rat kidney, AA is metabolized by endothelial cytochrome P-450-dependent enzymes to vasodilator metabolites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901256     DOI: 10.1161/01.res.68.4.958

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney.

Authors:  D Fulton; J C McGiff; J Quilley
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

2.  Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.

Authors:  S Arima; Y Endo; H Yaoita; K Omata; S Ogawa; K Tsunoda; M Abe; K Takeuchi; K Abe; S Ito
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  Apamin-sensitive, non-nitric oxide (NO) endothelium-dependent relaxations to bradykinin in the bovine isolated coronary artery: no role for cytochrome P450 and K+.

Authors:  G R Drummond; S Selemidis; T M Cocks
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  Signal transduction pathways involved in kinin B(2) receptor-mediated vasodilation in the rat isolated perfused kidney.

Authors:  K Bagaté; M Grima; J L Imbs; W D Jong; J J Helwig; M Barthelmebs
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 5.  Bisallylic hydroxylation and epoxidation of polyunsaturated fatty acids by cytochrome P450.

Authors:  E H Oliw; J Bylund; C Herman
Journal:  Lipids       Date:  1996-10       Impact factor: 1.880

6.  Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride.

Authors:  A O Oyekan; T Youseff; D Fulton; J Quilley; J C McGiff
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

7.  Cytochrome P450-dependent effects of bradykinin in the rat heart.

Authors:  D Fulton; K Mahboubi; J C McGiff; J Quilley
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

8.  Inhibition of NO-medicate responses by 7-ethoxyresorufin, a substrate and competitive inhibitor of cytochrome P450.

Authors:  C G Li; M J Rand
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.